SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
SGLT2i和GLP-1 RA治療對第1型糖尿病和腎血管結果的真實世界研究。
Diabetologia 2023-09-15
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
在接受胰高血糖素樣肽-1受體激動劑治療的日本2型糖尿病患者中，聯合使用鈉葡萄糖共同運輸蛋白2抑製劑改善了腎臟結果。
Cardiovasc Endocrinol Metab 2023-10-04
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
糖尿病患者合併使用SGLT2抑制劑、GLP-1受體激動劑和非類固醇MRA，與傳統治療相比，在預估終身心血管、腎臟和死亡益處方面的研究。
Circulation 2024-04-03
Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.
二型糖尿病患者合併使用鈉葡萄糖轉運蛋白2抑制劑和葡萄糖樣肽-1受體激動劑的效果和安全性：觀察性研究的系統性回顧和荟萃分析。
Cardiovasc Diabetol 2024-03-21
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
在患有第2型糖尿病和慢性腎臟病的患者中，先前藥物治療對聯合使用鈉葡萄糖共同轉運蛋白2抑製劑和葡萄糖樣肽-1受體激動劑治療的腎臟和心血管結果的影響。
Diabetes Obes Metab 2024-05-20
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
SGLT2 抑制劑與 GLP-1 受體激動劑在 2 型糖尿病中的腎臟與心血管效果比較。
J Am Coll Cardiol 2024-08-14
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
接受常規護理的2型糖尿病患者中，使用SGLT2抑制劑或GLP-1受體激動劑的匹配隊列比較腎臟結果。
Diabetologia 2024-08-23
Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions.
結合 GLP-1 受體激動劑和 SGLT-2 抑制劑以預防 2 型糖尿病的心血管疾病：一項包含多重網絡元回歸的系統性回顧。
World J Diabetes 2024-11-04
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.
一個還是兩個？SGLT2i或GLP1RA的聯合療法與單一療法之間心腎效應的比較。
Diabetes Obes Metab 2024-11-21